Literature DB >> 19514129

Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity.

Million Arefayene1, Santosh Philips, Donghua Cao, Sudharani Mamidipalli, Zeruesenay Desta, David A Flockhart, David S Wilkes, Todd C Skaar.   

Abstract

OBJECTIVES: Indoleamine 2,3-dioxygenase (IDO), a rate-limiting enzyme in tryptophan catabolism, is a key regulator of immune tolerance. We identified genetic variations in the IDO1 gene and evaluated their functional activities using in-vitro transfection studies.
METHODS: We resequenced the exons and the intron/exon borders of the IDO1 gene in 96 samples from the Coriell DNA Repository. To determine the functional effects of the coding variations that were predicted to have functional consequences, we expressed three of the variant cDNAs in COS-7 and HEK293 cells and determined their enzyme activity.
RESULTS: Seventeen variants were identified; three were nonsynonymous single nucleotide polymorphisms (Ala4Thr, Arg77His, Leu197Ile) and one was a 9 bp deletion in exon 7. Compared with the wild-type protein, the Arg77His and the 9 bp deletion resulted in significantly reduced protein expression and in nearly complete loss of enzyme activity. The allelic frequencies of these two functional variants were approximately 1% and were exclusively observed in the African-American samples.
CONCLUSION: We conclude that there are naturally occurring polymorphisms that render the human IDO1 gene nonfunctional and should result in reduced IDO activity in affected individuals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19514129     DOI: 10.1097/fpc.0b013e32832c005a

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  12 in total

Review 1.  Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.

Authors:  G C Prendergast; M Y Chang; L Mandik-Nayak; R Metz; A J Muller
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion.

Authors:  Alexander J Muller; James B DuHadaway; Mee Young Chang; Arivudinambi Ramalingam; Erika Sutanto-Ward; Janette Boulden; Alejandro P Soler; Laura Mandik-Nayak; Susan K Gilmour; George C Prendergast
Journal:  Cancer Immunol Immunother       Date:  2010-07-17       Impact factor: 6.968

3.  Indoleamine 2,3-dioxygenase 1 is a lung-specific innate immune defense mechanism that inhibits growth of Francisella tularensis tryptophan auxotrophs.

Authors:  Kaitian Peng; Denise M Monack
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

4.  Is the variant c.422+90G → A in intron 4 of indoleamine 2, 3 -dioxygenase (IDO) gene related to age related cataracts?

Authors:  M Mamata; G Sridhar; K Ravi Kumar Reddy; T Nagaraju; T Padma
Journal:  Mol Vis       Date:  2011-05-05       Impact factor: 2.367

5.  Identification of a variable number of tandem repeats polymorphism and characterization of LEF-1 response elements in the promoter of the IDO1 gene.

Authors:  Marion Soichot; Benjamin Hennart; Alaa Al Saabi; Audrey Leloire; Philippe Froguel; Claire Levy-Marchal; Odile Poulain-Godefroy; Delphine Allorge
Journal:  PLoS One       Date:  2011-09-27       Impact factor: 3.240

6.  Impact of immunosuppressive agents on the expression of indoleamine 2,3-dioxygenase, heme oxygenase-1 and interleukin-7 in mesangial cells.

Authors:  Guo-Biao Liang; Guang-Heng Luo; Ding-Su Bao; An-Jian Chen; Yong-Xiang Zhuang; Ya-Nan Guo; Xin Wang; Yuan-Liang Wang; Zong-Ping Chen; Yi-Ping Lu; You-Ping Li
Journal:  Mol Med Rep       Date:  2015-05-04       Impact factor: 2.952

7.  IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis.

Authors:  Antonella De Luca; Agostinho Carvalho; Cristina Cunha; Rossana G Iannitti; Lucia Pitzurra; Gloria Giovannini; Antonella Mencacci; Lorenzo Bartolommei; Silvia Moretti; Cristina Massi-Benedetti; Dietmar Fuchs; Flavia De Bernardis; Paolo Puccetti; Luigina Romani
Journal:  PLoS Pathog       Date:  2013-07-11       Impact factor: 6.823

Review 8.  From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases.

Authors:  Raghavan Chinnadurai; Edmund K Waller; Jacques Galipeau; Ajay K Nooka
Journal:  Biomed Res Int       Date:  2013-11-19       Impact factor: 3.411

9.  IDO1 and IDO2 non-synonymous gene variants: correlation with crohn's disease risk and clinical phenotype.

Authors:  Alexander Lee; Navya Kanuri; Yuanhao Zhang; Gregory S Sayuk; Ellen Li; Matthew A Ciorba
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

10.  Genetic associations of T cell cancer immune response-related genes with T cell phenotypes and clinical outcomes of early-stage lung cancer.

Authors:  Qinchuan Wang; Jianchun Gu; Linbo Wang; David W Chang; Yuanqing Ye; Maosheng Huang; Jack A Roth; Xifeng Wu
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.